NCT00048711
MPS VI, Mucopolysaccharidosis VI
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The purpose of the study is evaluate the efficacy, safety, and pharmacokinetics of weekly intravenous infusions of 1 mg/kg recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) in patients diagnosed with Mucopolysaccharidosis VI (MPS VI)
All
From 5 Years
No
N-acetylgalactosamine 4-sulfatase
Phase 2
Interventional
2002-03
2009-08-25
Novato, California, United States
*required fields
"*" indicates required fields